In India the several huge pharmaceutical companies comes under the Indian Pharmaceutical Alliance, has lead an initiative of Quality Forum (QF). Focusing terrain of the Quality Forum being Excellence and Quality, hence the Indian pharmaceutical industry’s problems regards to the regulatory to be looked in and solved.
To put a stop to the regulatory issues, the Medicines & Healthcare products Regulatory Agency (MHRA) and Central Drug Standards Controller Organization (CDSCO), the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) formed a group with the IPA is organizing a huge non theoretical conference on 23rd February of the year 2016 seeking Excellence and Quality.
Apart from those regulatory bodies, quality associated issues are taken care of by the IPA which is very interested to work with the US FDA to come up with a solution for all the quality related issues. The CEO’s of the major companies entirely support it at this venture, considering the regulators support, proper guidance and periodic dialogue, IPA is more confident about the Indian pharmaceutical industry’s challenge.
The other regulators in South East Asia to be noted are Indonesia National Drug and Food Control (INDFC), Korea Food and Drug Administration (KFDA), Philippines Bureau of Food and Drugs (BFAD), Thailand Food and Drug Administration (Thai FDA).
The proposition of IPA secretary general DG Shah assures the members that the goals are to grow the market share in sync with the goals of regulators who makes sure that the citizens get medicines of good quality. So that working together can result in it.
Other News
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
